77 related articles for article (PubMed ID: 20510251)
1. Development of a stochastic model for the efficacy of NRTIs using known mechanisms of action.
Khalili S; Monaco JM; Armaou A
J Theor Biol; 2010 Aug; 265(4):704-17. PubMed ID: 20510251
[TBL] [Abstract][Full Text] [Related]
2. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
Miller V; Larder BA
Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase.
Menéndez-Arias L
Virus Res; 2008 Jun; 134(1-2):124-46. PubMed ID: 18272247
[TBL] [Abstract][Full Text] [Related]
4. An introduction to nucleoside and nucleotide analogues.
Squires KE
Antivir Ther; 2001; 6 Suppl 3():1-14. PubMed ID: 11678469
[TBL] [Abstract][Full Text] [Related]
5. Nucleoside-analog resistance mutations in HIV-1 reverse transcriptase and their influence on polymerase fidelity and viral mutation rates.
Rezende LF; Prasad VR
Int J Biochem Cell Biol; 2004 Sep; 36(9):1716-34. PubMed ID: 15183340
[TBL] [Abstract][Full Text] [Related]
6. Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs).
Goldschmidt V; Marquet R
Int J Biochem Cell Biol; 2004 Sep; 36(9):1687-705. PubMed ID: 15183338
[TBL] [Abstract][Full Text] [Related]
7. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
Marcelin AG; Delaugerre C; Wirden M; Viegas P; Simon A; Katlama C; Calvez V
J Med Virol; 2004 Jan; 72(1):162-5. PubMed ID: 14635026
[TBL] [Abstract][Full Text] [Related]
8. Nucleotide analogue binding, catalysis and primer unblocking in the mechanisms of HIV-1 reverse transcriptase-mediated resistance to nucleoside analogues.
Selmi B; Deval J; Boretto J; Canard B
Antivir Ther; 2003 Apr; 8(2):143-54. PubMed ID: 12741627
[TBL] [Abstract][Full Text] [Related]
9. The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities.
Anderson PL; Kakuda TN; Lichtenstein KA
Clin Infect Dis; 2004 Mar; 38(5):743-53. PubMed ID: 14986261
[TBL] [Abstract][Full Text] [Related]
10. Intracellular interactions between nucleos(t)ide inhibitors of HIV reverse transcriptase.
Ray AS
AIDS Rev; 2005; 7(2):113-25. PubMed ID: 16092505
[TBL] [Abstract][Full Text] [Related]
11. Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors.
Domaoal RA; Demeter LM
Int J Biochem Cell Biol; 2004 Sep; 36(9):1735-51. PubMed ID: 15183341
[TBL] [Abstract][Full Text] [Related]
12. Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase.
Ren J; Stammers DK
Virus Res; 2008 Jun; 134(1-2):157-70. PubMed ID: 18313784
[TBL] [Abstract][Full Text] [Related]
13. Polymorphism and drug-selected mutations in the reverse transcriptase gene of HIV-2 from patients living in southeastern France.
Colson P; Henry M; Tivoli N; Gallais H; Gastaut JA; Moreau J; Tamalet C
J Med Virol; 2005 Mar; 75(3):381-90. PubMed ID: 15648062
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 reverse transcriptase inhibitors.
El Safadi Y; Vivet-Boudou V; Marquet R
Appl Microbiol Biotechnol; 2007 Jun; 75(4):723-37. PubMed ID: 17370068
[TBL] [Abstract][Full Text] [Related]
15. HIV-reverse transcriptase inhibition: inclusion of ligand-induced fit by cross-docking studies.
Ragno R; Frasca S; Manetti F; Brizzi A; Massa S
J Med Chem; 2005 Jan; 48(1):200-12. PubMed ID: 15634014
[TBL] [Abstract][Full Text] [Related]
16. Mg2+ dependency of HIV-1 reverse transcription, inhibition by nucleoside analogues and resistance.
Goldschmidt V; Didierjean J; Ehresmann B; Ehresmann C; Isel C; Marquet R
Nucleic Acids Res; 2006; 34(1):42-52. PubMed ID: 16394022
[TBL] [Abstract][Full Text] [Related]
17. Probing the molecular mechanisms of AZT drug resistance mediated by HIV-1 reverse transcriptase using a transient kinetic analysis.
Ray AS; Murakami E; Basavapathruni A; Vaccaro JA; Ulrich D; Chu CK; Schinazi RF; Anderson KS
Biochemistry; 2003 Jul; 42(29):8831-41. PubMed ID: 12873144
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic-pharmacodynamic relationship of NRTIs and its connection to viral escape: an example based on zidovudine.
von Kleist M; Huisinga W
Eur J Pharm Sci; 2009 Mar; 36(4-5):532-43. PubMed ID: 19150497
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
Balotta C; Berlusconi A; Pan A; Violin M; Riva C; Colombo MC; Gori A; Papagno L; Corvasce S; Mazzucchelli R; Facchi G; Velleca R; Saporetti G; Galli M; Rusconi S; Moroni M
Antivir Ther; 2000 Mar; 5(1):7-14. PubMed ID: 10846586
[TBL] [Abstract][Full Text] [Related]
20. l-2',3'-Didehydro-2',3'-dideoxy-3'-fluoronucleosides: synthesis, anti-HIV activity, chemical and enzymatic stability, and mechanism of resistance.
Chong Y; Gumina G; Mathew JS; Schinazi RF; Chu CK
J Med Chem; 2003 Jul; 46(15):3245-56. PubMed ID: 12852755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
